Literature DB >> 22426285

Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry.

Kees J Bronsema1, Rainer Bischoff, Nico C van de Merbel.   

Abstract

Following the increase in development of protein biopharmaceuticals, there is a growing demand for the sensitive and reliable quantification of these proteins in complex biological matrices such as plasma and serum to support (pre)-clinical research. In this field, ligand binding assays (LBAs) are currently the standard analytical technique, but in recent years, there is a trend towards the use of liquid chromatography hyphenated with (tandem) mass spectrometry (LC-MS/MS). One of the reasons for this trend is the possibility to use internal standards to correct for analytical variability and thus improve the precision and accuracy of the results. In the LC-MS/MS bioanalysis of small molecules, internal standardization is quite straightforward: either a stable-isotope labeled (SIL) form of the analyte or a structural analogue is used. For the quantification of biopharmaceutical proteins, the situation is more complex. Since the protein of interest is digested to a mixture of peptides, one of which is subsequently used for quantification, there are more options for internal standardization. A SIL form or a structural analogue of either the intact protein or the signature peptide can be used. In addition, a modified form of the SIL-peptide internal standard, containing one or more cleavable groups is a possibility, and an internal standard can be generated during the analysis by using differential derivatization techniques. In this paper we provide an overview of the different options for internal standardization in the field of absolute targeted quantification of protein biopharmaceuticals using LC-MS/MS, based on literature from 2003 to 2011. The advantages and disadvantages of the different approaches are evaluated both with regard to the correction they provide for the variability of the different steps of the analysis and with regard to their generic availability. As most of the approaches used lead to acceptable results in terms of accuracy and precision, we conclude that there currently is no clear preferable method for internal standardization in the field of protein quantification by LC-MS/MS. It is essential, however, that any step in the analysis that is not covered by the internal standard chosen, should be carefully optimized and controlled.
Copyright © 2012 Elsevier B.V. All rights reserved.

Mesh:

Substances:

Year:  2012        PMID: 22426285     DOI: 10.1016/j.jchromb.2012.02.021

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  14 in total

1.  Recommendations for validation of LC-MS/MS bioanalytical methods for protein biotherapeutics.

Authors:  Rand Jenkins; Jeffrey X Duggan; Anne-Françoise Aubry; Jianing Zeng; Jean W Lee; Laura Cojocaru; Dawn Dufield; Fabio Garofolo; Surinder Kaur; Gary A Schultz; Keyang Xu; Ziping Yang; John Yu; Yan J Zhang; Faye Vazvaei
Journal:  AAPS J       Date:  2014-11-13       Impact factor: 4.009

2.  Comprehensive analysis of protein digestion using six trypsins reveals the origin of trypsin as a significant source of variability in proteomics.

Authors:  Scott J Walmsley; Paul A Rudnick; Yuxue Liang; Qian Dong; Stephen E Stein; Alexey I Nesvizhskii
Journal:  J Proteome Res       Date:  2013-11-14       Impact factor: 4.466

Review 3.  Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry.

Authors:  Bo An; Ming Zhang; Jun Qu
Journal:  Drug Metab Dispos       Date:  2014-09-02       Impact factor: 3.922

4.  Proteomics of microparticles with SILAC Quantification (PROMIS-Quan): a novel proteomic method for plasma biomarker quantification.

Authors:  Michal Harel; Pazit Oren-Giladi; Orit Kaidar-Person; Yuval Shaked; Tamar Geiger
Journal:  Mol Cell Proteomics       Date:  2015-01-26       Impact factor: 5.911

5.  Directly coupled high-performance liquid chromatography-accelerator mass spectrometry measurement of chemically modified protein and peptides.

Authors:  Avi T Thomas; Benjamin J Stewart; Ted J Ognibene; Kenneth W Turteltaub; Graham Bench
Journal:  Anal Chem       Date:  2013-03-20       Impact factor: 6.986

6.  Biomarker Assay Validation by Mass Spectrometry.

Authors:  Carmen Fernández-Metzler; Brad Ackermann; Fabio Garofolo; Mark E Arnold; Binodh DeSilva; Huidong Gu; Omar Laterza; Yan Mao; Mark Rose; Faye Vazvaei-Smith; Rick Steenwyk
Journal:  AAPS J       Date:  2022-05-09       Impact factor: 4.009

7.  Quantitative determination of betamethasone sodium phosphate and betamethasone dipropionate in human plasma by UPLC-MS/MS and a bioequivalence study.

Authors:  Man-Yun Chen; Yong-Jun Tang; Yi-Cheng Wang; Chong-Zhi Wang; Chun-Su Yuan; Yao Chen; Zhi-Rong Tan; Wei-Hua Huang; Hong-Hao Zhou
Journal:  Anal Methods       Date:  2016-03-29       Impact factor: 2.896

8.  Effects of calibration approaches on the accuracy for LC-MS targeted quantification of therapeutic protein.

Authors:  Eslam Nouri-Nigjeh; Ming Zhang; Tao Ji; Haoying Yu; Bo An; Xiaotao Duan; Joseph Balthasar; Robert W Johnson; Jun Qu
Journal:  Anal Chem       Date:  2014-03-21       Impact factor: 6.986

9.  The application of Gaussian mixture models for signal quantification in MALDI-TOF mass spectrometry of peptides.

Authors:  John Christian G Spainhour; Michael G Janech; John H Schwacke; Juan Carlos Q Velez; Viswanathan Ramakrishnan
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

10.  Rapid liquid chromatography-mass spectrometry quantitation of glucose-regulating hormones from human islets of Langerhans.

Authors:  Matthew J Donohue; Robert T Filla; Daniel J Steyer; Wesley J Eaton; Michael G Roper
Journal:  J Chromatogr A       Date:  2020-12-15       Impact factor: 4.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.